The research about blood pressure circadian rhythm and standard antihypertensive therapy in type 2 diabetes mellitus with hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16007955

Enrollment

Unknown

Registered

2016-02-20

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus with hypertension

Interventions

A1:morning administration in dipper group

A2:evening administration in dipper group

B1:morning administration in non-dipper group

B2:evening administration in non-dipper group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Form eighteen to seventy-five; 2. Type 2 diabetes mellitus with mild to moderate hypertension; 3. Daytime activity and nighttime sleep routine; 4. The patient accepted this clinical trial; 5. The patient administered 150mg irbesartan.

Exclusion criteria

Exclusion criteria: 1. ALT or AST passed 2 tines, Cr passed 95umol/L; 2. Secondary hypertension and type 2 diabetes mellitus; 3. Nightwork employment; 4. CCVD (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation,cerebral apoplexy); 5. Pregnancy and lactation; 6. Intolerance to ABPM; 7. Researcher think who's unsuited this trial.

Design outcomes

Primary

Measure	Time frame
ambulatory blood pressure monitoring (ABPM);Intima-media thickness (IMT);homocysteine (Hcy);	—

Countries

China

Contacts

Public ContactWei Ping

wp301@sina.com+86 13983780786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026